Intellia Therapeutics News

Institutional Owners May Consider Drastic Measures as Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Recent US$125m Drop Adds to Long-term Losses

Key Insights Significantly high institutional ownership implies Intellia Therapeutics' stock price is sensitive to their trading actions The top 11 shareholders own 50% of the company Recent sale

Simply Wall StApr 26 06:06 ET

Express News | Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $29 Price Target

Moomoo 24/7Apr 23 13:11 ET

Intellia Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/23/2024 30.98% Wedbush → $29 Reiterates Neutral → Neutral 02/23/2024 44.53% Goldman Sachs → $32 Downgra

BenzingaApr 23 13:10 ET

Intellia Therapeutics Welcomes New Principal Accounting Officer

TipRanksApr 15 16:32 ET

2 Stocks Down 30% to Buy Right Now

Yahoo FinanceApr 14 05:55 ET

Cathie Wood Goes Bargain Hunting. 2 Stocks She Bought This Week.

Yahoo FinanceApr 12 04:50 ET

Bull Market and Beyond: 3 Stocks Just Waiting to Soar

Yahoo FinanceApr 9 04:50 ET

Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX), Legend Biotech (LEGN) and Intellia Therapeutics (NTLA)

TipRanksApr 8 21:50 ET

Intellia Therapeutics (NASDAQ:NTLA Shareholders Incur Further Losses as Stock Declines 9.9% This Week, Taking Three-year Losses to 65%

Yahoo FinanceApr 6 08:47 ET

Biotech Roundtable: Who Will Bring the Next CRISPR Drug to Market?

Seeking AlphaApr 2 11:36 ET

Shareholders in Intellia Therapeutics (NASDAQ:NTLA) Are in the Red If They Invested Three Years Ago

Investing in stocks inevitably means buying into some companies that perform poorly. But long term Intellia Therapeutics, Inc. (NASDAQ:NTLA) shareholders have had a particularly rough ride in the las

Simply Wall StMar 30 10:48 ET

Better Cathie Wood Stock: Moderna Vs. Intellia

Yahoo FinanceMar 28 05:55 ET

Update: Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals

(Updates with Regeneron's response in the third paragraph and the latest stock move of Intellia and Regeneron in the fifth paragraph.) Intellia Therapeutics (NTLA) said in a Friday filing that it has

MT NewswiresMar 25 11:46 ET

Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals

Intellia Therapeutics (NTLA) said in a Friday filing that it has decided to end its 2020 agreement with Regeneron Pharmaceuticals (REGN) on developing gene editing products directed to factor IX, a bl

MT NewswiresMar 22 14:11 ET

Intellia Opts Out of Hemophilia Pact With Regeneron

Seeking AlphaMar 22 12:40 ET

Express News | Intellia Therapeutics On March 19, Notified Regeneron Pharmaceuticals That Co Is Opting Out Of Its Factor IX Co-Development And Co-Funding Agreement

Moomoo 24/7Mar 22 09:29 ET

Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study

Yahoo FinanceMar 19 13:06 ET

Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis With Cardiomyopathy

CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today

GlobeNewswireMar 18 07:30 ET

Is Intellia Therapeutics Stock a Buy Now?

The Motley FoolMar 9 09:45 ET

Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst

The Motley FoolMar 6 10:35 ET